...

CCO Treatment Updates

Novel Developments in the Treatment of Malignant Mesothelioma

Novel Developments in the Treatment of Malignant Mesothelioma

Module 1 of 1

Faculty:

Marcelo C. DaSilva, MD, FACS, FCCPDavid J. Sugarbaker, MD
  • Marcelo C. DaSilva, MD, FACS, FCCP
  • David J. Sugarbaker, MD

CREDIT INFORMATION

Release Date: 01/26/10

Expiration Date: 01/25/11


Physicians: maximum of 0.75 AMA PRA Category 1 Credits™

Status: Please log in to view status
Begin the Module

Marcelo C. DaSilva, MD, FACS, FCCP, and David J. Sugarbaker, MD, provide an in-depth review of the latest developments in the clinical management of patients with malignant mesothelioma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the epidemiological patterns, pathogenesis, and histology of mesothelioma
  • Articulate the key diagnostic features of malignant pleural mesothelioma
  • Cite clinical trial data supporting the use of specific first-line chemotherapy regimens and the role of multimodality therapy for the treatment of malignant pleural mesothelioma
  • Discuss recent data on emerging targeted agents for the treatment of malignant pleural mesothelioma

Abstract

Interactive Virtual Presentation

Contemporary Management of Malignant Pleural Mesothelioma

Faculty:

Nicholas J. Vogelzang, MD
  • Nicholas J. Vogelzang, MD

CREDIT INFORMATION

Release Date: 01/21/10

Expiration Date: 01/20/11


Physicians: maximum of 0.75 AMA PRA Category 1 Credits™

Status: Please log in to view status
Begin the Virtual Presentation

Nicholas J. Vogelzang, MD, provides an overview of current diagnostic and treatment approaches for patients with malignant pleural mesothelioma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Use optimal approaches for the correct diagnosis and staging of malignant pleural mesothelioma in clinical practice
  • Apply clinical trial data supporting the use of doublet chemotherapy when treating patients with unresectable malignant pleural mesothelioma
  • Discuss recent findings on the potential role for anti-VEGF therapy in treating patients with malignant pleural mesothelioma
  • Summarize data on new agents in preclinical and phase I and II clinical development for the treatment of malignant pleural mesothelioma

Slideset: Contemporary Management of Malignant Pleural Mesothelioma

Download the Slideset


Nicholas J. Vogelzang, MD, reviews current data that suggest new ways of treatment for this previously difficult-to-treat disease.


Format: Microsoft PowerPoint (.ppt) | File size: 1.41 MB | Date posted: 1/21/2010


Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Contact Info

Educational grants provided by:

Educational grants support only the CME-certified components of this program.